CompletedPhase 2Results posted

A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Who Are Currently on Metformin Monotherapy

A Randomized, Double-blind, Placebo-controlled, Multiple-dose, Phase II Study to Evaluate the Efficacy and Safety of 3 Months of Twice-a-week Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy

Lead sponsor

ConjuChem

Asset

CJC-1134-PC

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Type 2 diabetes

Eligibility highlights

•BMI 27-45•HbA1c 7.1-11%

Primary endpoint

•HbA1c

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00674466

Org study IDDM200-102

Timeline

Milestones

Study first posted2008-05-07estimated

Last update posted2017-06-02actual

Results first posted2017-06-02actual

Study start2008-03 (month precision)

Primary completion2008-11actual (month precision)

Study completion2008-11actual (month precision)

Assets

Investigational agents

CJC-1134-PC

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age25 Years

SexAll

Healthy volunteersNot accepted

Eligibility criteria

Major Inclusion Criteria:

•BMI: 27 to 45 kg/m2

•Stable Type 2 diabetes mellitus for at least 3 months, as defined by the Investigator

•Stable life-style, i.e. diet \& physical activity, as determined by the Investigator

•Stable metformin daily dose ≥1000 mg for at least 3 months

•Glycosylated hemoglobin (HbA1c) at screening ≥ 7.1% and ≤ 11%

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Weight & body composition

2 endpoints

Secondary/protocol endpoint

Reduction in Fasting Body Weight From Baseline

Time frame:Screening and Day 85

change from baseline, improvement

Secondary/registry result

Reduction in Fasting Body Weight From Baseline

Time frame:Screening and Day 85

change from baseline, improvement

Posted result

Group	Mean · kg	95% CI
1.5 mg CJC-1134-PC	-1.17	-
1.5 mg or 2.0 mg CJC-1134-PC	-0.90	-
Placebo	-0.39	-

Glycemic / diabetes

4 endpoints

Primary/protocol endpoint

Reduction of HbA1c From Baseline

Time frame:Screening and Day 85

descriptive

Primary/registry result

Reduction of HbA1c From Baseline

Time frame:Screening and Day 85

descriptive

Posted result

Group	Mean · Percent (%)	95% CI
1.5 mg CJC-1134-PC	-1.29	-
1.5 mg or 2.0 mg CJC-1134-PC	-0.55	-
Placebo	-0.34	-

Secondary/protocol endpoint

Reduction in Fasting Plasma Glucose From Baseline

Time frame:Screening and Day 85

change from baseline, improvement

Secondary/registry result

Reduction in Fasting Plasma Glucose From Baseline

Time frame:Screening and Day 85

change from baseline, improvement

Posted result

Group	Mean · mg/dL	95% CI
1.5 mg CJC-1134-PC	-5.88	-
1.5 mg or 2.0 mg CJC-1134-PC	4.12	-
Placebo	12.12	-

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.